Similar articles

• Hormone therapy and the impact of estrogen intake on the risk of ovarian cancer.

  Glud E, Kjaer SK, Thomsen BL, Høgdall C, Christensen L, Høgdall E, Bock JE, Blaakaer J. Glud E, et al. Arch Intern Med. 2004 Nov 8;164(20):2253-9. doi: 10.1001/archinte.164.20.2253. Arch Intern Med. 2004. PMID: 15534163
• Postmenopausal hormone replacement therapy: ovarian cancer.

  [No authors listed] [No authors listed] Prescrire Int. 2016 Jan;25(167):16. Prescrire Int. 2016. PMID: 26942255
• Hormone therapy and ovarian cancer.

  Trémollieres F, Lopès P, Gompel A; Groupe d'Etude sur la Ménopause et le Vieillissement hormonal. Trémollieres F, et al. Lancet. 2015 Sep 12;386(9998):1038. doi: 10.1016/S0140-6736(15)00139-7. Lancet. 2015. PMID: 26382992 No abstract available.
• Estrogen-progestogen replacement therapy and ovarian cancer: an update.

  La Vecchia C. La Vecchia C. Eur J Cancer Prev. 2006 Dec;15(6):490-2. doi: 10.1097/01.cej.0000205026.14515.de. Eur J Cancer Prev. 2006. PMID: 17106327 Review.
• [Hormone therapies and ovarian cancer].

  Grenman S, Salmi T. Grenman S, et al. Duodecim. 2002;118(4):349-56. Duodecim. 2002. PMID: 12233039 Review. Finnish. No abstract available.